Reagent: HIV-1 CH167 Infectious Molecular Clone

Catalog Number: 13544
Lot Number: 190369
Release Category: C

Provided: 5 μg of dried purified DNA stabilized in DNAstable PLUS

Cloning Vector: pUC57
Ampicillin resistant

Cloning Site: MluI/NotI cloning site
The size of the insert is approximately 10,000 bp.

GenBank: KC156213

Host Strain: Plasmids can be propagated in STBL2 cells and grown at 37°C. Larger plasmids may benefit from growth at 30°C. This construct may also be grown in other competent cells.

Description: A full length replication competent, infectious HIV-1 subtype C CH167 molecular clone. The virus produced by this molecular clone utilizes the co-receptor CCR5.

Special Characteristics: This construct is approximately 14,000 bp including the insert.
Viral RNA was extracted from plasma samples from an HIV-1 infected female from Malawi. Consensus sequences were generated with clonally expanded viral sequences in the chronic infection samples. The sequences were cloned and combined within a single plasmid vector (pBR322 or pUC57) as a complete proviral genome.

This reagent is currently being provided as dried purified DNA stabilized in DNAstable PLUS. Please see the notice for additional information and the protocol for reconstitution of dried DNA reagents. Dried DNA Notice

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Recommended Storage: Keep the reagent at room temperature in a dry storage cabinet or in a moisture barrier bag.

Contributor: Dr. Feng Gao


NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 CH167 Infectious Molecular Clone from Dr. Feng Gao (cat# 13544)." Also include the reference cited above in any publications.

Scientists at for-profit institutions or who intend commercial use of this reagent must contact the Duke University-Office of Research Contracts at the following email addresses: david.kordys@duke.edu or bilyana.georgieva@duke.edu, before the reagent can be released.

Last Updated: December 22, 2020